


In re Application of: Sawynok et al.  
Application No.: 09/700,625  
Filing Date: February 1, 2001  
Page 2 of 14

PATENT  
Attorney Docket No.: DALHO1290-1  
(028614-1102)

37. (Twice amended) A composition for local administration comprising a second or third generation antidepressant other than trazodone, and a vehicle suitable for local administration, wherein the second or third generation antidepressant has a structure:



wherein:

Ar<sub>3</sub> is a substituted N-containing heterocyclic ring,

Y is either an aryl group fused to the heterocyclic ring, or one or two substituents selected from the group consisting of alkyl, alkyloxy, arylalkyl, arylalkyloxy, aryl, heteroaryl substituents, and combinations thereof comprising a total of about 4 to 8 carbons attached to Ar<sub>3</sub>,

X is an alkyl group comprising 2 to 5 carbon atoms linking Ar<sub>3</sub> and Ar<sub>4</sub>,

Ar<sub>4</sub> is a piperazine attached to X by a first nitrogen atom of Ar<sub>4</sub>, and

Q is a benzene ring optionally substituted with a biocompatible halogen and attached to Ar<sub>4</sub> at a second nitrogen atom of Ar<sub>4</sub>.

Please add new claims 74-83 as follows.

74. (New) A composition for topical administration comprising:  
a second or third generation antidepressant, and  
a vehicle suitable for topical administration,  
wherein the second or third generation antidepressant is selected from the group consisting of amoxapine, maprotiline, trazodone, bupropion, mirtazapine, venlafaxine, nefazodone, reboxetine, and fluoxetine, and

wherein said vehicle is selected from the group consisting of a cream, a lotion, a gel, an ointment, a spray, a patch, a polymer stabilized crystal, and an aerosol.

75. (New) The composition of claim 74, wherein the composition further comprises a penetration enhancing agent.

In re Application of: Sawynok et al.  
Application No.: 09/700,625  
Filing Date: February 1, 2001  
Page 3 of 14


PATENT  
Attorney Docket No.: DALHO1290-1  
(028614-1102)

\*  
76. (New) The composition of claim 74, wherein the composition further comprises a neutralizing agent.

77. (New) A composition for topical administration comprising:  
a second or third generation antidepressant, and  
a vehicle suitable for topical administration,  
wherein the second or third generation antidepressant is selected from the group consisting of amoxapine, maprotiline, trazodone, bupropion, mirtazapine, venlafaxine, nefazodone, reboxetine, and fluoxetine, and  
wherein said vehicle is a slow release delivery vehicle.

78. (New) The composition of claim 77, wherein the slow release delivery vehicle is selected from the group consisting of a liposome, a microcapsule, and a polymer stabilized crystal.

79. (New) A composition for topical administration comprising a second or third generation antidepressant, and a vehicle suitable for topical administration, wherein the second or third generation antidepressant has a structure:



wherein:

$\text{Ar}_3$  is a substituted N-containing heterocyclic ring,

Y is either an aryl group fused to the heterocyclic ring, or one or two substituents selected from the group consisting of alkyl, alkyloxy, arylalkyl, arylalkyloxy, aryl, heteroaryl substituents, and combinations thereof comprising a total of about 4 to 8 carbons attached to  $\text{Ar}_3$ ,

X is an alkyl group comprising 2 to 5 carbon atoms linking  $\text{Ar}_3$  and  $\text{Ar}_4$ ,

$\text{Ar}_4$  is a piperazine attached to X by a first nitrogen atom of  $\text{Ar}_4$ , and

Q is a benzene ring optionally substituted with a biocompatible halogen and attached to  $\text{Ar}_4$  at a second nitrogen atom of  $\text{Ar}_4$ , and

In re Application of: Sawynok et al.  
Application No.: 09/700,625  
Filing Date: February 1, 2001  
Page 4 of 14

PATENT  
Attorney Docket No.: DALHO1290-1  
(028614-1102)

wherein said vehicle is selected from the group consisting of a cream, a lotion, a gel, an ointment, a spray, a patch, a polymer stabilized crystal, and an aerosol.

80. (New) The composition of claim 79, wherein the composition further comprises a penetration enhancing agent.

81. (New) The composition of claim 79, wherein the composition further comprises a neutralizing agent.

82. (New) A composition for topical administration comprising a second or third generation antidepressant, and a vehicle suitable for topical administration, wherein the second or third generation antidepressant has a structure;



wherein:

Ar<sub>3</sub> is a substituted N-containing heterocyclic ring,

Y is either an aryl group fused to the heterocyclic ring, or one or two substituents selected from the group consisting of alkyl, alkyloxy, arylalkyl, arylalkyloxy, aryl, heteroaryl substituents, and combinations thereof comprising a total of about 4 to 8 carbons attached to Ar<sub>3</sub>,

X is an alkyl group comprising 2 to 5 carbon atoms linking Ar<sub>3</sub> and Ar<sub>4</sub>,

Ar<sub>4</sub> is a piperazine attached to X by a first nitrogen atom of Ar<sub>4</sub>, and

Q is a benzene ring optionally substituted with a biocompatible halogen and attached to Ar<sub>4</sub> at a second nitrogen atom of Ar<sub>4</sub>, and

wherein said vehicle is a slow release delivery vehicle.

83. (New) The composition of claim 82, wherein the slow release delivery vehicle is selected from the group consisting of a liposome, a microcapsule, and a polymer stabilized crystal.